Details for Patent: 12,194,030

Which drugs does patent 12,194,030 protect, and when does it expire?

Patent 12,194,030 protects UBRELVY and is included in one NDA.

This patent has forty-one patent family members in thirteen countries.

Summary for Patent: 12,194,030

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Inventor(s):	Joel M. Trugman, Ramesh BOINPALLY, Abhijeet Jakate, Michelle Finnegan
Assignee:	Allergan Pharmaceuticals International Ltd
Application Number:	US18/593,308
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,194,030
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,194,030

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No						ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A MODERATE CYP3A4 INHIBITOR
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No						ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A WEAK CYP3A4 INHIBITOR

International Family Members for US Patent 12,194,030

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015214502
Australia	2019226239
Australia	2021245229
Australia	2021409718
Australia	2023258317
Australia	2025220825
Brazil	112016017999